Yescarta Approved for Second-Line Treatment of Large B-Cell Lymphoma
The approval was based on data from the phase 3 ZUMA-7 trial.
Diagnosis & Disease Information
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Navigation Strategies for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy and Hematologic Cancers
An overview of CAR-T therapy with a discussion of the potential barriers unique to this treatment.
Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Cumulative Illness Rating Scale Has Prognostic Significance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers found that CIRS scores are prognostic for overall and progression-free survival in patients with R/R DLBCL being evaluated for CAR-T therapy.
Corticosteroids May Be Effective for Managing Cytokine Release Syndrome Associated With CAR-T Therapy
Researchers sought to determine if corticosteroids can be used to effectively manage CRS in patients undergoing CAR-T therapy without negatively influencing outcomes.
Early Steroid Use May Mitigate Adverse Effects Associated With Axicabtagene Ciloleucel CAR-T Therapy
In a safety expansion of the ZUMA-1 study, researchers found that steroids may reduce incidence of CRS and neurologic events associated with CAR-T therapy in patients with relapsed/refractory large B cell lymphoma.
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Medicare to Cover CAR-T Therapy for Leukemia, Lymphoma
Chimeric antigen receptor T-cell therapy boosts a patient’s own immune cells.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...